Rakovina Therapeutics Inc · TSXV:RKV
Rakovina Therapeutics — Investor Presentation (September 2021)
16 slides from Rakovina Therapeutics's investor presentation, September 2021
Slide 1: Revolutionizing Cancer Treatment with DNA Damage Response Inhibitor Technology
TSX-V: RKV Revolutionizing Cancer Treatment with DNA Damage Response Inhibitor Technology Corporate Presentation Q3 2021
Slide 2: Forward Looking Statements
Forward Looking Statements Certain forward-looking statements contained herein constitute “forward- receipts as disclosed herein; additional sources of funding, including looking information” (collectively, “forward-looking information”) within the grants and funding from partners; the Company’s abi
Slide 3: Cancer is Still a Leading Cause of Death; We Need Better Treatments
Cancer is Still a Leading Cause of Death; We Need Better Treatments • With an aging western population, cancer occurrences are expected to rise • Chemotherapy is the current gold standard treatment, also kills many healthy cells, causing considerable patient health issues • Although many cancers can
Slide 4: Rakovina Therapeutics' DDRi Technology Can Potentially Reduce Cancer Onset and Reoccurrence
Rakovina Therapeutics’ DNA Damage Response Inhibitor (DDRi) Technology Can Potentially Reduce the Onset and Reoccurrence of Several Cancers Note: Image is for illustrative purposes only. Health claims have yet to be authorized by any regulatory agency and are only used to express the potential of th
Slide 5: DNA Damage and Cancer
DNA Damage and Cancer • Tens of thousands of DNA damaging events occur in our cells every day • DNA Damage Response (DDR) is a collection of processes within our cells that identify and correct DNA damage • Many cancers harbor a defect in natural DDR mechanisms that allow tumor cells to evade the hu
Slide 6: Exploits Cancer's "Achilles' Heel"
Many cancers hijack DDR system defects allowing tumors to Normal Cell develop and grow unchecked Pre-cancerous Rakovina DDRi Full compliment of DNA repair Cell Mutation = DDR-loss Exploits Cancer’s pathways A B A B of pathway “A” “Achilles’ Heel” • Cancer cells with a DDR Some cancers become heavily
Slide 7: Big-Pharma Invests Over $25 B into DDRi
Big-Pharma Invests Over $25 B into DDRi Target Firm Amount Year Type Details $14.0B 2016 Acq. Phase 3 $5.1B 2019 Acq. FDA Approved DNA-damage response is a top research priority (2020 Annual Report) $3.0B 2020 Invest. Collaboration Collaboration $3.0B 2020 Invest. Option License $1.3B 2021 Invest. C
Slide 8: Major Cancer Markets with Unmet Medical Needs are an Opportunity for Rakovina DDRi
Major Cancer Markets with Unmet Medical Needs are an Opportunity for Rakovina DDRi Triple Negative Prostate Ovarian Breast Cancer Cancer Cancer $13.0B $12.8B $6.7B Rakovina’s Strategy: Build upon the success of Poly (ADP-Ribrose) Polymerase inhibitors (PARPi), the 1st “blockbuster” DDR, by, developi
Slide 9: Rakovina Intellectual Property
Rakovina Intellectual Property kt-2000 kt-3000 kt-4000 Next-generation PARPi Dual-function DDRi DNA-damaging DDRi Owned patents and patent- Exclusive option to patent- Exclusive option to patent- pending applications extend pending applications extend pending applications extend to at least 2032 to
Slide 10: Special Affiliation with UBC
Special Affiliation with UBC • Lead candidate optimization and preclinical development conducted in collaboration with the University of British Columbia • Dedicated “in-house” team under the direction of Prof. Mads Daugaard, a recognized leader in the DDRi field • State-of-the-Art facilities • Effi
Slide 11: Development Timeline & Milestones
Development Timeline & Milestones Pre-Clinical Development / Lead Stage: Phase 1/2a Trials Pivotal Phase 2b/3 Trials FDA Approval Optimization Details: Lead optimization of novel drug candidates: • Clinical trials to establish safety Clinical trials to demonstrate: • Regulatory approval • Activity a
Slide 12: Leadership
Leadership Jeffrey Bacha, BSc, MBA 25+ year healthcare and life science executive. Extensive experience in securing public and private funding and building Executive Chairman strong scientific teams to meet ambitious business goals. Mads Daugaard, PhD Recognized leader in the field of DNA-damage res
Slide 13: Capitalization
Capitalization Rakovina Therapeutics Inc. has been initially capitalized with ~$4.7 million working capital through an amalgamation with TSX-V listed Vincero Capital Corp. and concurrent private placement in a CPC qualifying transaction. Common shares outstanding 69,808,000 Escrowed common shares (4
Slide 14: Selected Financial Results
Selected Financial Results For the three As at months ended Selected Financial Statements of net loss and June 30, 2021 June 30, 2021 Information comprehensive loss data: $ $ Cash & cash equivalents 3,821,301 Research & Development 486,400 Working capital 3,946,952 General and administrative 351,183
Slide 15: Potential Upcoming Scientific & Business Conference Events (2021-22)
Potential Upcoming Scientific & Business Conference Events (2021-22) ✓ AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Oct 2022) • JCA-AACR Precision Medicine International Conference (Sept 2021) • Understanding & Targeting the DNA Repair Pathways (Oct 2021) • O
Slide 16: Contact
Rakovina David Hyman, CFO Therapeutics Inc. (403) 613-1453 | david.hyman@rakovinatherapeutics.com Joseph Garcia, Partner, Blake Cassels and Graydon LLP Legal Advisors (604) 631-3307 | joseph.garcia@blakes.com Davidson & Company LLP Auditor Contact (604) 900-9230 | davidson@davidson-co.com Odyssey Tr
Rakovina Therapeutics — Investor Presentation (September 2021) on 6ix